|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||104.97 - 105.01|
|52 Week Range||48.28 - 105.01|
|PE Ratio (TTM)||32.01|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||99.20|
Bioverativ formed a perfect double bottom, a key chart pattern for growth stock hunters, and broke out ahead of its big 61% gain on news it's being bought by Sanofi.
Stock Monitor: Alder Biopharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 08, 2018 / Active-Investors.com has just released a free research report on Bioverativ Inc. (NASDAQ: BIVV ). If you ...
NEW YORK, March 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Bioverativ Inc. , a global biopharmaceutical company dedicated to transforming the lives of people with rare blood disorders, today announced that the first patient has been dosed in the Phase 3 clinical program of its investigational therapy BIVV009 for cold agglutinin disease .
NEW YORK , March 2, 2018 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600: S&P MidCap 400 constituent IPG Photonics Corp. (NASD: ...
Stock Monitor: Bioverativ Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 22, 2018 / Active-Investors.com has just released a free research report on Voyager Therapeutics, Inc. (NASDAQ: VYGR ...
Bioverativ Inc (NASDAQ:BIVV) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
Bioverativ Inc. , a global biopharmaceutical company dedicated to transforming the lives of people with rare blood disorders, today announced the publication of a retrospective analysis investigating the use of ELOCTATE® for immune tolerance induction .
NEW YORK, NY / ACCESSWIRE / February 8, 2018 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a boutique securities firm headquartered at the Empire State Building in New ...
Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi Commences Tender Offer for Acquisition of Bioverativ Inc. Paris - February 8, 2018 - Sanofi announced today that on February 7, 2018 it ...
Vertex Pharmaceuticals, Amgen and Johnson and Johnson were among the big movers in the biotech and pharmaceutical sectors.
NEW YORK, NY / ACCESSWIRE / February 1, 2018 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Bioverativ Inc. ("Bioverativ" or the ...
Sanofi will acquire Bioverativ (BIVV) for $105 per share. Bioverativ spun from Biogen (BIIB) on Feb. 1, 2017. BIVV has returned 129%. Spin-Offs are 5x more likely to be acquired. Spin-Offs outperform the general market. Both this spin BIVV and BIIB are great examples of this over performance.
PARIS/LONDON (Reuters) - French drugmaker Sanofi (SASY.PA) has agreed to buy Belgian biotech company Ablynx (ABLX.BR) for 3.9 billion euros (3.41 billion pounds), beating Novo Nordisk (NOVOb.CO) and marking its second big deal this month after buying Bioverativ (BIVV.O). The transaction is a further sign of accelerating merger and acquisition (M&A) activity in the global biotech sector and comes after Ablynx rejected a 2.6 billion euro offer from Denmark's Novo Nordisk. Sanofi said on Monday it would pay 45 euros per share in cash for Ablynx, a premium of 21 percent over its closing price on Friday, and more than double the price before Novo went public with its initial bid.
The Law Offices of Vincent Wong are investigating the Board of Directors of Bioverativ Inc. for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Sanofi.
It was a volatile day for Eli Lilly and Co (NYSE:LLY) on Jan. 22. LLY stock ultimately hit a low of $82.40 before slingshotting higher and ending the day flat at $85.44. Maybe it was just in flux as the industry was busy digesting Celgene Corporation (NASDAQ:CELG) buying Juno Therapeutics Inc (NASDAQ:JUNO) for $9 billion and Sanofi SA (ADR) (NYSE:SNY) acquiring Bioverativ Inc (NASDAQ:BIVV) for $11.6 billion.
NEW YORK, Jan. 24, 2018 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Bioverativ Inc. ("BIVV" or the "Company") (BIVV) in connection with the proposed acquisition of the Company by French drugmaker Sanofi S.A. ("Sanofi"). Under the terms of the acquisition agreement, the Company's shareholders will receive $105.00 in cash for each BIVV share they own. WeissLaw is investigating whether BIVV's Board acted to maximize shareholder value prior to entering into the agreement. Notably, in its latest financial release, the Company announced impressive financial results. It reported a 27.2% annual increase in revenue and Non-GAAP operating margin of 45.7%.
Bioverativ Inc (NASDAQ: BIVV ) agreed to be acquired by Sanofi SA (ADR) (NYSE: SNY ) in an $11.6-billion all-cash deal, with the offer price valuing each of Bioverativ shares at $105. The offer price represents ...
Moody's Investors Service, ("Moody's") has today affirmed the A1 long-term ratings of Sanofi and its guaranteed subsidiary. The affirmation follows the 22 January announcement of Sanofi that ...
The following statement is being issued by Levi & Korsinsky, LLP: